Posted by Lindsey Winhoffer on Apr 17th, 2024
Biogen (NASDAQ:BIIB – Get Free Report) had its price objective decreased by investment analysts at Wedbush from $245.00 to $213.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral”...
More of this article »